Title: Synthesis and biological evaluation of new phenothiazine derivatives bearing a pyrazole unit as protein farnesyltransferase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20121115
Title: Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.
Journal: Journal of molecular medicine (Berlin, Germany) 20120201
Title: The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.
Journal: Leukemia 20110701
Title: Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Journal: Journal of medicinal chemistry 20101014
Title: Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
Journal: Anti-cancer agents in medicinal chemistry 20100201
Title: Design, Synthesis and Evaluation of Novel 1-(Substituted Acetyl)-4-(10-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine-11-Ylidene)piperidines as Antitumor Agents and Farnesyl Protein Transferase Inhibitors.
Journal: Indian journal of pharmaceutical sciences 20100101
Title: BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.
Journal: Blood 20091105
Title: Analysis of the eukaryotic prenylome by isoprenoid affinity tagging.
Journal: Nature chemical biology 20090401
Title: Chronic myelogenous leukemia stem cells: What's new?
Journal: Current hematologic malignancy reports 20090401
Title: Ethyl methanesulphonate in a parenteral formulation of BMS-214662 mesylate, a selective farnesyltransferase inhibitor: formation and rate of hydrolysis.
Journal: Pharmaceutical development and technology 20090101
Title: BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Journal: Blood 20080301
Title: Characterization of cancer stem cells in chronic myeloid leukaemia.
Journal: Biochemical Society transactions 20071101
Title: Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070615
Title: Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology 20060701
Title: Group IVC cytosolic phospholipase A2gamma is farnesylated and palmitoylated in mammalian cells.
Journal: Journal of lipid research 20051001
Title: Development of farnesyl transferase inhibitors: a review.
Journal: The oncologist 20050901
Title: Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
Journal: Molecular pharmacology 20050601
Title: Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050601
Title: Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Journal: Current drug targets 20050501
Title: Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050420
Title: Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050410
Title: A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050301
Title: [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Journal: Bulletin du cancer 20050301
Title: Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Journal: Leukemia & lymphoma 20041101
Title: Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
Journal: Leukemia 20041001
Title: Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
Journal: Biochemistry 20040608
Title: Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models.
Journal: Cancer research 20040601
Title: A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040415
Title: Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040401
Title: Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20040209
Title: Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
Journal: Journal of medicinal chemistry 20040129
Title: Farnesyl transferase inhibitors in myeloid malignancies.
Journal: Blood reviews 20030901
Title: Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Journal: Clinical lymphoma 20030801
Title: Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Journal: Current oncology reports 20030301
Title: Farnesyl transferase inhibitors in the treatment of breast cancer.
Journal: Expert opinion on investigational drugs 20030301
Title: Targeting RAS signalling pathways in cancer therapy.
Journal: Nature reviews. Cancer 20030101
Title: BMS-214662 (Bristol-Myers Squibb).
Journal: IDrugs : the investigational drugs journal 20030101
Title: Farnesyl transferase inhibitors as anticancer agents.
Journal: European journal of cancer (Oxford, England : 1990) 20020901
Title: [New therapeutic targets and strategies in lung cancer].
Journal: Archivos de bronconeumologia 20020801
Title: Agents targeting ras signaling pathway.
Journal: Current pharmaceutical design 20020101
Title: Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
Journal: Cancer research 20011015
Title: Farnesyltransferase inhibitors.
Journal: Seminars in oncology 20011001
Title: Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
Journal: Journal of medicinal chemistry 20001005
Title: Hunt JT, et al. Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem. 2000 Oct 5;43(20):3587-95.
Title: Rose WC, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001 Oct 15;61(20):7507-17.
